1-5 of 5
Elizabeth A. McMillan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 5019: Next-generation DYRK1A inhibitors as a new therapeutic approach for the treatment of hematological malignancies

Matthew C. Jarvis, Gopi Mittapalli, Emily Creger, Chelsea Nora, Maureen Ibanez, Deepti Bhat, Brian Hofilena, Josh Stewart, Elizabeth A. McMillan, Hadi Falahatpisheh, Chi-Ching Mak, Michael White, John S. Hill, Carine Bossard
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5019.
https://doi.org/10.1158/1538-7445.AM2023-5019
Published: 04 April 2023
View article titled, Abstract 5019: Next-generation DYRK1A inhibitors as a new therapeutic approach for the treatment of hematological malignancies
Journal Articles

Abstract 3928: The pan-CLK/DYRK inhibitor cirtuvivint selectively disrupts alternative splicing and has broad anti-tumor activity in preclinical models

Elizabeth A. McMillan, Carine Bossard, Emily Creger, Carsten Merkwirth, Raffaella Pippa, Matthew Jarvis, Krishna Sriram, Melinda Pedraza, Maureen Ibanez, Deepti Bhat, Carolyn Lai, Josh Stewart, Brian Eastman, Chi-Ching Mak, Michael A. White, Darrin Beaupre
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 3928.
https://doi.org/10.1158/1538-7445.AM2022-3928
Published: 15 June 2022
View article titled, Abstract 3928: The pan-CLK/DYRK inhibitor cirtuvivint selectively disrupts alternative splicing and has broad anti-tumor activity in preclinical models
Journal Articles

Abstract 1160: SAM competitive PRMT5 inhibitor PF06939999 demonstrates antitumor activity in splicing dysregulated NSCLC with decreased liability of drug resistance

Kristen Jensen-Pergakes, John Tatlock, Karen Maegley, Indrawan McAlpine, Michele McTigue, Tao Xie, Christopher Dillon, Yuli Wang, Shinji Yamazaki, Noah Spiegel, Manli Shi, Amy Nemeth, Natalie Miller, Eleanore Hendrickson, Hieu Lam, John Sherrill, Wei Liu, Ya-Li Deng, Chi-Yeh Chung, Elizabeth A. McMillan, Prakash Palde, Alexei Brooun, John Braganza, Susan E. Kephart, Robert Kumpf, Ryan Patman, Eugene Rui, Stephanie Scales, Michelle Tran-Dube, Fen Wang, Martin Wythes, Thomas Paul
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1160.
https://doi.org/10.1158/1538-7445.AM2021-1160
Published: 01 July 2021
View article titled, Abstract 1160: SAM competitive PRMT5 inhibitor PF06939999 demonstrates antitumor activity in splicing dysregulated NSCLC with decreased liability of drug resistance
Journal Articles

HORMAD1 Is a Negative Prognostic Indicator in Lung Adenocarcinoma and Specifies Resistance to Oxidative and Genotoxic Stress

Brandt A. Nichols, Nathaniel W. Oswald, Elizabeth A. McMillan, Kathleen McGlynn, Jingsheng Yan, Min S. Kim, Janapriya Saha, Prema L. Mallipeddi, Sydnie A. LaDuke, Pamela A. Villalobos, Jaime Rodriguez-Canales, Ignacio I. Wistuba, Bruce A. Posner, Anthony J. Davis, John D. Minna, John B. MacMillan, Angelique W. Whitehurst
Journal: Cancer Research
Cancer Res (2018) 78 (21): 6196–6208.
https://doi.org/10.1158/0008-5472.CAN-18-1377
Published: 01 November 2018
View article titled, HORMAD1 Is a Negative Prognostic Indicator in Lung Adenocarcinoma and Specifies Resistance to Oxidative and Genotoxic Stress
Open the PDF for HORMAD1 Is a Negative Prognostic Indicator in Lung Adenocarcinoma and Specifies Resistance to Oxidative and Genotoxic Stress in another window
Includes: Supplementary data
Journal Articles

TBK1 Provides Context-Selective Support of the Activated AKT/mTOR Pathway in Lung Cancer

Jonathan M. Cooper, Yi-Hung Ou, Elizabeth A. McMillan, Rachel M. Vaden, Aubhishek Zaman, Brian O. Bodemann, Gurbani Makkar, Bruce A. Posner, Michael A. White
Journal: Cancer Research
Cancer Res (2017) 77 (18): 5077–5094.
https://doi.org/10.1158/0008-5472.CAN-17-0829
Published: 14 September 2017
View article titled, TBK1 Provides Context-Selective Support of the Activated AKT/mTOR Pathway in Lung Cancer
Open the PDF for TBK1 Provides Context-Selective Support of the Activated AKT/mTOR Pathway in Lung Cancer in another window
Includes: Supplementary data